Business
Kiora completes global licensing map for KIO-301 with South Korea deal to Chong Kun Dang
Kiora Pharmaceuticals (Nasdaq: KPRX) has licensed South Korean development and commercialization rights for KIO-301, its molecular photoswitch for retinitis...
Lilly expands vaccine push with Amplitude's next-generation RNA platform
Eli Lilly and Company (NYSE: LLY) has entered a research collaboration and licensing agreement with Boston-based Amplitude Therapeutics to discover and...
Oblenio exercises LBL-051 option, securing worldwide rights from Leads Biolabs
Oblenio Bio, the Cambridge, Massachusetts-based spinout formed by Aditum Bio around a trispecific T-cell engager (TCE) licensed from China-based Nanjing...
Onco-Innovations secures option on LAG-3 small-molecule program from Ifowonco
Calgary-based Onco-Innovations Limited (CBOE CA: ONCO / OTCQB: ONNVF) has signed a non-binding letter of intent with Ifowonco Informatics Incorporated to...
Edesa Biotech raises USD 25m to fuel vitiligo Phase II
Canada-based Edesa Biotech, Inc. (Nasdaq: EDSA) announced the pricing of a USD 25 million underwritten public offering on August 19, 2026, with proceeds...
Akiram secures lutetium-177 supply deal for CD44v6 radiopharmaceutical
Sweden-based Akiram Therapeutics has secured a supply agreement with Germany-based ITM Isotope Technologies Munich SE for non-carrier-added lutetium-177...
Network Bio raises USD 50m for patient tissue-trained AI platform
Palo Alto-based Network Bio has launched with USD 50 million in financing to build disease-specific AI models trained on multimodal patient tissue, blood,...
Jocasta cuts Unity from α-klotho IP chain with direct UCSF deal
Scottsdale, Arizona-based Jocasta Neuroscience has secured a direct license from the University of California, San Francisco (UCSF) covering α-klotho-based...
KaliVir raises USD 14m as oncolytic virus clears first IV cohort
Pittsburgh, Pennsylvania-based KaliVir Immunotherapeutics, Inc. has closed a USD 14 million extension of its Series A financing to fund continued clinical...
Tolerance Bio licenses clinical-stage IL-7 therapy to enter thymic function studies
Philadelphia-based Tolerance Bio has licensed efineptakin alfa (NT-I7), a long-acting IL-7 fusion protein, from South Korea-based NeoImmuneTech (KOSDAQ:...
Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo
South San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and Genentech, a member of the Roche Group, announced a clinical collaboration to evaluate...
BioArctic expands BrainTransporter platform from neurodegeneration to glioblastoma with Mesenkia collaboration
Sweden-based BioArctic AB (Nasdaq Stockholm: BIOA B) and preclinical-stage Mesenkia Therapeutics have signed a research collaboration agreement to generate...
Lilly completes USD 10m payment for preclinical Alzheimer's GSM from AlzeCure
Eli Lilly has received full delivery of the USD 10 million upfront payment under its collaboration and out-licensing agreement with Sweden-based AlzeCure...
Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia win
Cambridge, Massachusetts-based Amylyx Pharmaceuticals (Nasdaq: AMLX) announced a USD 350 million underwritten public offering of common stock, with proceeds...
GSK secures preclinical dengue antibody from Chugai
GSK has secured an exclusive, worldwide license from Japan-based Chugai Pharmaceutical Co., Ltd. (Tokyo: 4519) for AID351, a preclinical pan-serotype...
The AllSci Brief
Free, systematic R&D and deal news. Daily.